ALK pathway may have played an important role in the disease.[21] A phase I dose-escalation trial of the selective MET/ALK inhibitor crizotinib showed a long-term partial response in one patient with IMT who carried an ALK translocation.[22] The different ALK gene rearrangement rates may contribute to the different treatment results of local mass complete resection by hysteroscope since the patient with a local recurrence has a higher ALK translocation rate. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.